Key result
Cyclophosphamide administration establishes an experimental mouse model of HFpEF.
Why the study?
Does intraperitoneal cyclophosphamide induce a model of heart failure with preserved ejection fraction in outbred mice?
Does intraperitoneal cyclophosphamide induce a model of heart failure with preserved ejection fraction in outbred mice?
Intraperitoneal injection of cyclophosphamide in mice can serve as an experimental model for heart failure with preserved ejection fraction and drug toxicity studies.
Answers are grounded in this paper and cite their sources.
Offers experimental HFpEF model in mice; leaves open clinical translation and requires independent validation.
The article presents the results of reproduction of the cyclophosphane model of heart failure. Outbred mice weighing 18–26 g at the onset of the experiment were used. All mice were divided into two groups with 10 animals in each. The first group was injected intraperitoneally with cyclophosphamide at a dose of 15 mg/kg, five times for 21 days (day 1, 5, 10, 15, and 21). The second group was intact animals. EchoCG was performed on the animals twice: baseline before the experiment (point 1) and one week after the last injection (point 2, day 28). The presented experimental model may be used for the study of drug toxicity prevention methods, as well as a model of heart failure with preserved left ventricular ejection fraction.
No takes yet. Share an insight, caveat, or question.
Evgenieva et al. (2024) studied Heart failure (n=20). Cyclophosphamide vs. Intact animals was evaluated on Echocardiography parameters at day 28. Cyclophosphamide administered at /kg over 21 days in mice serves as an experimental model of heart failure with preserved left ventricular ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: